MAPT and Alzheimer disease: As cis P-tau is an early disease driver and blood biomarker in incipient AD patients and cis P-tau mAb is in clinical trials, these results not only discover a previously unknown early pathogenic mechanism in PE and its causal molecular link with dementia, but also offer an early biomarker and effective immunotherapy for PE.